Replies to post #650636 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Reardon is "in bed with" Enterome EO2041

https://www.enterome.com/news-events/enterome-to-present-updated-safety-immunogenicity-and-efficacy-data-from-its-phase-1-2-trial-of-eo2401-in-recurrent-glioblastoma-rosalie-study-at-sitc-2022/

Inovio GMB-001

https://ascopost.com/news/june-2022/immunotherapy-combination-in-newly-diagnosed-glioblastoma/

So many reasons to want to throw stones in the path of NWBO

Here is a summary of the prospects for best case approval of the drugs EO2041, GBM-001:


EO2041 is a novel drug candidate for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. In preclinical studies, EO2041 has shown promising anti-tumor activity and has been well-tolerated. A Phase I clinical trial of EO2041 is currently ongoing, and the results of this trial will provide more information about the drug's safety and efficacy in humans. If EO2041 is found to be safe and effective in the Phase I trial, it will be further investigated in Phase II and Phase III clinical trials. The best-case scenario for EO2041 is that it will be approved by the FDA for the treatment of GBM within the next 5-10 years.

GBM-001 is another novel drug candidate for the treatment of GBM. It is a monoclonal antibody that targets a protein called epidermal growth factor receptor (EGFR), which is often overexpressed in GBM tumors. In preclinical studies, GBM-001 has shown promising anti-tumor activity and has been well-tolerated. A Phase I clinical trial of GBM-001 is currently ongoing, and the results of this trial will provide more information about the drug's safety and efficacy in humans. If GBM-001 is found to be safe and effective in the Phase I trial, it will be further investigated in Phase II and Phase III clinical trials. The best-case scenario for GBM-001 is that it will be approved by the FDA for the treatment of GBM within the next 5-10 years.